+36-1-880-8500 info@cominnex.com

News

v

X‑Chem Acquires ComInnex

Extending Functional and Global Leadership in Small Molecule Drug Discovery

X-Chem, the pioneer of DNA-encoded library (DEL) technology and recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of ComInnex, a leading European provider of synthetic chemistry services and novel chemical technologies to support early-stage drug discovery.

Read more

v

PhotoCube has been selected as a finalist for the 2021 R&D Top100 Awards

We are proud to announce that the multi-wavelength batch and flow photoreactor, PhotoCube (developed together with ThalesNano) has been selected as a finalist for the 2021 R&D Top100 Awards in Analytical/Test category.

Read more

v

UPPTHERA and ComInnex sign research collaboration for the development of novel Proteolysis-Targeting Chimera candidates

UPPTHERA, a pharmaceutical venture company aiming for new drugs based on targeted protein degradation (TPD) technology and ComInnex, a specialist chemistry group with expertise in the design and synthesis of small molecules for drug discovering will accelerate the development of new proteolysis targeting chimeras (commonly known as PROTAC) or Molecular Glues. Within the framework of the collaboration, UPPTHERA and ComInnex will co-verify a number of potential novel E3 ligase ligands which have been designed by ComInnex and co-develop TPD chimera molecules to which the novel E3 ligase ligands will be applied.

Read the full press release

v

Degrader Building Blocks with Inhibitor of Apoptosis Protein (IAP) In Silico-Derived Ligands

We are very proud to be collaborating with Merck Millipore to develop degrader building blocks, in this case for IAP and containing three novel, in silico-derived lead compounds. Together, these reagents accelerate synthesis of IAP-mediated degraders at early stages of TPD research and assessment.

Click below to explore the Advantages of IAP In Silico-Derived Ligands!

Further information

v

Novel approach for insect control: E3 ligase ligand library for potential degradation of vital insect proteins

Come and see how we are applying protein degradation techniques to crop protection at our poster at the ACS Fall meeting.

Further information

v

InnoStudio Launches a Consortium for Developing Coronavirus Drugs Based on Simultaneous Research in Space and Earth Environments

We are happy to announce to be involved in drug research project – advancing our knowledge of synthesis into space … the final frontier! Curious where it will lead us and hope others will join this intitiative too!

Read the full press release

v

COVID-19 statement

ComInnex Inc. is open for business as usual, accepting chemistry projects (large or small). To keep things moving we offer rapid onboarding (fast contract turnaround) and favourable rates.

If chemistry is currently a bottleneck come and talk to us!

COVID-19 statement

ComInnex takes seriously the threat to its staff and customers of the corona virus. We comply with all local regulations and are committed to global efforts to “flatten the curve”. To this extent we have implemented a range of measures to keep our facilities operating as well as possible under current circumstances.

v

Photocatalytic reactions in flow

We are proud to share with you that our Associate Principal Scientist, Gellert Sipos held two presentations at the ACS fall meeting. He talked about photocatalytic reactions in flow and on the application of a novel mutliwavelength photoreactor for batch and flow chemistry developed by ComInnex Inc. and ThalesNano Inc.

Further information

v

InnoStudio, ComInnex and ThalesNano enter into photochemistry collaboration with Technical University Eindhoven

Proud to share with you that ComInnex Inc. has entered a photochemistry collaboration with Eindhoven University of Technology.

Further information

v

Global chemistry service and research organization reinforces its commitment to deliver the highest quality services to the life science industry

ComInnex Inc. announces ISO 9001:2015 certification – Global chemistry service and research organization reinforces its commitment to deliver the highest quality services to the life science industry.

Read the full press release

v

Open collaboration project

ComInnex, Inc. has started an open collaboration type of project to support its activities on designing and synthesizing a large number of novel chemical building blocks to be used subsequently by companies in creating and / or enriching their DNA-encoded libraries. The project currently involves large pharmaceutical companies as well as a biotech service provider from all around the globe, and it is still open to join.

Please contact info@cominnex.com for further information

v

Affinity-Based Lead Discovery Using DNA Encoded Chemistry

ComInnex, Inc. has attended the Chemical Biology session “Affinity-Based Lead Discovery Using DNA Encoded Chemistry” at SLAS2018, where interesting developments from this very exciting area were discussed with key opinion leaders.

Please contact info@cominnex.com for further information

v

Dr. Ferenc Darvas is awarded an ACS Fellowship

We are happy to announce that in recognition of his outstanding achievements towards the field of chemistry, Dr. Ferenc Darvas, the president of ThalesNano Inc., president of ComInnex Inc. and a number of other companies that he has founded in the field of chemistry research and innovation, has been honored and selected as a member of the 2016 class of Fellows of the American Chemical Society.

Read the Pdf version of the press release here

v

Design of Novel Peptide Drug Conjugate Warheads as Novel Potential Anticancer Agents

ComInnex Inc. has been awarded a grant (NVKP_16-1-2016-0036) by the Hungarian government for a consortium working on the development of bioconjugates and modules for the targeted treatment of high mortality tumor diseases. The project is for 3 years and was started in January 2017 with a close collaboration with Semmelweis University and Eotvos Lorand University. New anticancer drug candidates are targeted to be developed based on a close cooperation of the members. The essence of the research is around the development of new Peptide (Antibody) Drug Conjugates (ADCs).

Further information

v

Development of a flow chemistry and pyrolysis platform for pharmaceutical, cosmetics and agrochemical applications in combination with novel nanoformulation processes

ComInnex Inc. has been awarded a grant (KMR_12-1-2012-0218.) for the development of a flow chemistry and pyrolysis platform for pharmaceutical, cosmetics and agrochemical applications in combination with novel nanoformulation processes.

Further information

v

Alex Drijver joins the ComInnex Inc. as CEO

ComInnex, Inc. announced that Alex Drijver joined the company as CEO.

Read the pdf version of the press release here

Developing a high-throughput innovative chemistry and informatics platform to support pharmaceutical drug discovery projects

ComInnex, Inc. has been awarded a grant (GINOP-2.1.1-15-2015-00069) for developing a high-throughput innovative chemistry and informatics platform to support pharmaceutical drug discovery projects.

Further information